Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Govert Johan Schouten is active.

Publication


Featured researches published by Govert Johan Schouten.


Biotechnology and Bioengineering | 2008

Serum-free transient protein production system based on adenoviral vector and PER.C6 technology: High yield and preserved bioactivity†

Menzo Jans Emco Havenga; Lennart Holterman; I. Melis; Shirley Smits; Jorn Kaspers; E. Heemskerk; R.A.A. van der Vlugt; Martin Koldijk; Govert Johan Schouten; G. Hateboer; K. Brouwer; Ronald Vogels; Jaap Goudsmit

Stable E1 transformed cells, like PER.C6, are able to grow at scale and to high cell densities. E1‐deleted adenoviruses replicate to high titer in PER.C6 cells whereas subsequent deletion of E2A from the vector results in absence of replication in PER.C6 cells and drastically lowers the expression of adenovirus proteins in such cells. We therefore considered the use of an ΔE1/ΔE2 type 5 vector (Ad5) to deliver genes to PER.C6 cells growing in suspension with the aim to achieve high protein yield. To evaluate the utility of this system we constructed ΔE1/ΔE2 vector carrying different classes of protein, that is, the gene coding for spike protein derived from the Coronavirus causing severe acute respiratory syndrome (SARS‐CoV), a gene coding for the SARS‐CoV receptor or the genes coding for an antibody shown to bind and neutralize SARS‐CoV (SARS‐AB). The ΔE1/ΔE2A‐vector backbones were rescued on a PER.C6 cell line engineered to constitutively over express the Ad5 E2A protein. Exposure of PER.C6 cells to low amounts (30 vp/cell) of ΔE1/ΔE2 vectors resulted in highly efficient (>80%) transduction of PER.C6 cells growing in suspension. The efficient cell transduction resulted in high protein yield (up to 60 picogram/cell/day) in a 4 day batch production protocol. FACS and ELISA assays demonstrated the biological activity of the transiently produced proteins. We therefore conclude that ΔE1/ΔE2 vectors in combination with the PER.C6 technology may provide a viable answer to the increasing demand for high quality, high yield recombinant protein. Biotechnol. Bioeng. 2008;100: 273–283.


Archive | 2002

Recombinant protein production in a human cell

Abraham Bout; Guus Hateboer; Karina Cornelia Verhulst; Alphonsus Gerardus Cornelis Maria Uytdehaag; Govert Johan Schouten


Archive | 2009

Production of vaccines

Maria Grazia Pau; Alphonsus Gerardus Cornelius Maria Uytdehaag; Govert Johan Schouten


Archive | 2000

Means and methods for fibroblast-like or macrophage-like cell transduction

Ronald Vogels; Govert Johan Schouten; Abraham Bout; Menzo Jans Emco Havenga


Archive | 2005

Vaccines against West Nile Virus

Alphonsus Gerardus Cornelis Maria Uytdehaag; Govert Johan Schouten; Jaap Goudsmit


Archive | 1999

Improved aav vector production

Govert Johan Schouten; Abraham Bout; Maria Grazia Pau


Archive | 2000

Recombinant protein production in a human cell comprising at least one E1 protein of adenovirus

Abraham Bout; Guus Hateboer; Govert Johan Schouten; Alphonsus Uytdenhaag; Karina Cornelia Verhulst


Archive | 2003

Methods for the identification of antiviral compounds

Ronald Hendrik Peter Brus; Govert Johan Schouten; Alphonsus Gerardus Cornelis Maria Uytdehaag


Archive | 2000

Recombinant protein production in a human cell using sequences encoding adenovirus e1 protein

Guus Hateboer; Karina Cornelia Verhulst; Govert Johan Schouten; Alphonsus Gerardus Cornelis Maria Uytdehaag; Abraham Bout


Archive | 2008

USE OF ADENOVIRAL VECTOR FOR SYNOVIAL CELL TRANSDUCTION

Ronald Vogels; Govert Johan Schouten; Abraham Bout

Researchain Logo
Decentralizing Knowledge